Palliative chemotherapy or watchful waiting? A vignettes study among oncologists.

PURPOSE To determine the preferences of oncologists for palliative chemotherapy or watchful waiting and the factors considered important to that preference. METHODS Sixteen vignettes (paper case descriptions), varying on eight patient and treatment characteristics, were designed to assess the oncologists' preferences. Their strength of preference was rated on a 7-point scale. An orthogonal main effects design provided a subset of all possible combinations of the characteristics, allowing estimations of the relative weights of the presented characteristics. A written questionnaire was sent to a random sample of oncologists (N = 1,235). RESULTS The response rate was 67%, and 697 questionnaires were available for analysis. Eighty-one percent of the respondents were male. The mean age was 46 years. We found considerable variation among the oncologists. No major associations between physician characteristics and preferences were found. Of the patient and treatment characteristics affecting treatment preference, age was the strongest predictor, followed by the patient's wish to be treated and the expected survival gain. Other patient and treatment characteristics had a limited effect on preferences, except for psychologic distress, which had no independent impact. CONCLUSION Patients will encounter different decisions depending on their oncologists' preferences and their own personal background. Therefore, to ensure adequate information for decision-making processes, decision aids are proposed.

[1]  A. Stiggelbout,et al.  Choices in oncology: factors that influence patients' treatment preference , 1994, Quality of Life Research.

[2]  D. Cella,et al.  Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Espinàs,et al.  Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial , 2001, BMJ : British Medical Journal.

[4]  A. Oza,et al.  Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R Smith,et al.  PubMed Central: creating an Aladdin's cave of ideas , 2001, BMJ : British Medical Journal.

[6]  A. Zietman,et al.  Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. , 2000, JAMA.

[7]  A. Goldhirsch,et al.  Depression and degree of acceptance of adjuvant cytotoxic drugs , 2000, The Lancet.

[8]  K. Kurth,et al.  Quality of Life Assessment in Patients with Hormone–Resistant Prostate Cancer Treated with Epirubicin or with Epirubicin plus Medroxy Progesterone Acetate – Is It Feasible? , 2000, European Urology.

[9]  J. Klijn,et al.  Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. , 2000, European journal of cancer.

[10]  E. Eisenhauer,et al.  Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J W Peabody,et al.  Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. , 2000, JAMA.

[12]  J. Daurès,et al.  Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose. , 2000, American journal of clinical oncology.

[13]  E. Rutgers,et al.  Interpretive Review : Feasibility and Effects of Decision Aids , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  D. Cella,et al.  Age‐related differences in the quality of life of breast carcinoma patients after treatment , 1999, Cancer.

[15]  C. Charles,et al.  Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. , 1999, Social science & medicine.

[16]  A. Norman,et al.  Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Vos Clinical decision making in cardiopulmonary resuscitation , 1999 .

[18]  C. Alonso,et al.  Small-cell lung cancer in the elderly--is age of patient a relevant factor? , 1999, Acta oncologica.

[19]  I D Graham,et al.  Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. , 1999, Journal of the National Cancer Institute. Monographs.

[20]  R. Rubens,et al.  Do patients with advanced breast cancer benefit from chemotherapy? , 1998, British Journal of Cancer.

[21]  H. Welch,et al.  Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews , 1998, BMJ.

[22]  T. Hickish,et al.  Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. , 1998, British Journal of Cancer.

[23]  I. Tannock,et al.  Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  I. Tannock Conventional cancer therapy: promise broken or promise delayed? , 1998, The Lancet.

[25]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[26]  C. Charles,et al.  Doing Nothing is No Choice: Lay Constructions of Treatment Decision‐making Among Women with Early‐stage Breast Cancer , 1998 .

[27]  C. Charles,et al.  Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). , 1997, Social science & medicine.

[28]  J. Hainsworth,et al.  Mitoxantrone, 5‐fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) in first‐line chemotherapy for patients with metastatic breast carcinoma , 1997 .

[29]  N. Thatcher,et al.  Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. , 1997, European journal of cancer.

[30]  G. Henze Childhood acute lymphoblastic leukaemia. , 1997, European journal of cancer.

[31]  J. Wennberg Presidential Guest Speaker: Practice Variations and the Challenge to Leadership , 1996 .

[32]  J. Wennberg Practice variations and the challenge to leadership. , 1996, Spine.

[33]  M. Barry,et al.  Patient Reactions to a Program Designed to Facilitate Patient Participation in Treatment Decisions for Benign Prostatic Hyperplasia , 1995, Medical care.

[34]  D. Cella,et al.  Someone to live for: social well-being, parenthood status, and decision-making in oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Muss,et al.  Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. D. Haes,et al.  Deciding to cease active cancer treatment: issues in process and outcome , 1995 .

[37]  I. Tannock,et al.  Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Tannock,et al.  Goals of palliative cancer therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Porzsolt,et al.  Goals of palliative cancer therapy: scope of the problem. , 1993, Cancer treatment reviews.

[40]  J. Sloan,et al.  Decision making during serious illness: what role do patients really want to play? , 1992, Journal of clinical epidemiology.

[41]  I. Tannock,et al.  Use of a physician-directed questionnaire to define a consensus about management of breast cancer: implications for assessing costs and benefits of treatment. , 1992, Journal of the National Cancer Institute. Monographs.

[42]  C. Minkovitz,et al.  Oncologists vary in their willingness to undertake anti-cancer therapies. , 1991, British Journal of Cancer.

[43]  H. Llewellyn-Thomas,et al.  Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. , 1991, Social science & medicine.

[44]  S. Piantadosi,et al.  Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  W. Gregory,et al.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. , 1990, BMJ.

[46]  D. Tritchler,et al.  Cancer Patients: Their Desire for Information and Participation in Treatment Decisions , 1989, Journal of the Royal Society of Medicine.

[47]  G. Kitagawa,et al.  Akaike Information Criterion Statistics , 1988 .

[48]  L. Degner,et al.  Life-death decisions in health care , 1987 .